Skip to content
Yog Pharma
Urology and men's health5-alpha reductase inhibitor

Finasteride is a 5-alpha reductase inhibitor indicated for benign prostatic hyperplasia and male pattern hair loss. We supply it to US manufacturers of tablets.

CAS98319-26-7372.5 g/molC23H36N2O2
2D structure of Finasteride.

Data from PubChem (CID 57363) and FDA’s substance registry

CAS number

98319-26-7

Molecular formula

C23H36N2O2

Molecular weight

372.5g/mol

FDA UNII

IUPAC name

(1S,3aS,3bS,5aR,9aR,9bS,11aS)-N-tert-butyl-9a,11a-dimethyl-7-oxo-1,2,3,3a,3b,4,5,5a,6,9b,10,11-dodecahydroindeno[5,4-f]quinoline-1-carboxamide

InChIKey

DBEPLOCGEIEOCV-WSBQPABSSA-N

Appearance
White crystalline powder, melting near 250 °C.
Solubility
Practically insoluble in water. Freely soluble in chloroform and in lower alcohols.

Typical description, from FDA-approved labeling and pharmacopoeial monographs. The specification sent with your quote is the controlling document for any source.

Worth settling with your inquiry

A potent API that needs containment in handling, because women who are or may be pregnant should not be exposed to it. It has two polymorphs; state the form.

On the US market

Reference product
ProscarNDA 020180
Approved ANDAs
14 with a marketed product
Approved forms and strengths
  • Tablet 1 mg, 5 mg

Single-ingredient products in FDA’s Drugs@FDA database, retrieved November 2026. The brand name belongs to its owner and identifies the reference product only.

Grade

USP or Ph. Eur. where a monograph exists, or your own specification.

Quantities

From development quantities for formulation work to commercial supply.

Packaging

To the manufacturer’s standard, typically fiber or HDPE drums with double polyethylene liners.

Regulatory filings

US DMF and CEP availability depends on the source. We confirm the filing status in writing with the quotation.

Documents available with a quote

  • Specification and certificate of analysis
  • Safety data sheet
  • Method of analysis
  • DMF letter of authorization, where a US DMF is filed
  • GMP certificate and inspection history of the site
  • Residual solvents and elemental impurities statements
  • Nitrosamine risk assessment
  • TSE/BSE statement

Need something else for your QA file? Email info@yogpharma.com